

Hans-Jürgen Mller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11233107/hans-jurgen-moller-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

546
papers

37,357
citations

99
h-index

169
g-index

569
ext. papers

41,822
ext. citations

4.7
avg, IF

6.97
L-index

#	Paper	IF	Citations
546	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022 , 1	5.1	1
545	Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. <i>Journal of Affective Disorders</i> , 2021 , 299, 73-84	6.6	1
544	The ongoing discussion on termination of life on request. A review from a German/European perspective. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021 , 25, 2-18	2.4	5
543	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. <i>Journal of Psychiatric Research</i> , 2021 , 136, 543-551	5.2	2
542	Medication management of antipsychotic treatment in schizophrenia – a narrative review. <i>Human Psychopharmacology</i> , 2021 , 36, e2765	2.3	2
541	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 171-180	5.8	3
540	Subsyndromal generalised anxiety disorder: operationalisation and epidemiology - a systematic literature survey. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021 , 1-10	2.4	1
539	Classification Systems of Mental Disorders: Where Did We Go Wrong? 2020 , 193-203		0
538	What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020 , 270, 661-671	5.1	3
537	Polymorphisms in CRYBB2 encoding B2-crystallin are associated with antisaccade performance and memory function. <i>Translational Psychiatry</i> , 2020 , 10, 113	8.6	1
536	Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study. <i>NeuroImage: Clinical</i> , 2019 , 21, 101624	5.3	9
535	Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophrenia Research</i> , 2019 , 209, 185-192	3.6	2
534	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 2-16	3.8	15
533	Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. <i>Pharmacopsychiatry</i> , 2019 , 52, 180-185	2	
532	Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis. <i>Microbial Biotechnology</i> , 2019 , 13, 120-127	3.3	4
531	Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 183-193	5.1	27
530	Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1 year after their first in-patient treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 459-468	5.1	10

529	Therapeutic efficacy of the Ginkgo special extract EGb761 within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 173-189	3.8	33
528	Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2018 , 27,	4.3	22
527	Silexan in anxiety disorders: Clinical data and pharmacological background. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 412-420	3.8	76
526	Efficacy of extended clinical management, group CBT, and group plus individual CBT for major depression: Results of a two-year follow-up study. <i>Journal of Affective Disorders</i> , 2018 , 238, 570-578	6.6	4
525	Possibilities and limitations of DSM-5 in improving the classification and diagnosis of mental disorders. <i>Psychiatria Polska</i> , 2018 , 52, 611-628	1.3	2
524	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 2-58	3.8	89
523	A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3). <i>Journal of Affective Disorders</i> , 2018 , 228, 173-177	6.6	7
522	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 814-821	5.8	17
521	A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 29-38	3.8	11
520	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 82-90	2.4	35
519	Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?. <i>Pharmacopsychiatry</i> , 2017 , 50, 136-144	2	3
518	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. <i>Cognitive Neuropsychiatry</i> , 2017 , 22, 280-297	2	9
517	Why are new antidepressants failing to make the grade for approval?. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 641-643	4	2
516	Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 166-176	2.4	75
515	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017 , 174, 216-229	11.9	408
514	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 86-119	3.8	38
513	How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 721-730	5.8	32
512	Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 303-313	5.1	6

511	Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 195-204	2.2	17
510	Psychiatrie, Psychosomatik, Psychotherapie [Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes 2017 , 3-37		
509	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie 2017 , 1321-1338		
508	Psychopharmakotherapie [klinisch-empirische Grundlagen 2017 , 795-842		
507	Prinzipien der Methodik empirischer Forschung in der Psychiatrie 2017 , 463-490		
506	Standardisierte Befunddiagnostik in der Psychiatrie 2017 , 577-600		
505	Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification. <i>Schizophrenia Research</i> , 2016 , 173, 159-165	3.6	40
504	Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. <i>BMC Psychiatry</i> , 2016 , 16, 153	4.2	6
503	Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. <i>Microbial Biotechnology</i> , 2016 , 10, 17-27	3.3	15
502	Mobility behaviour and driving status of patients with mental disorders - an exploratory study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016 , 20, 40-6	2.4	14
501	The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. <i>Journal of Psychopharmacology</i> , 2016 , 30, 40-7	4.6	27
500	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016 , 249, 84-90	2.9	7
499	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia. <i>Schizophrenia Research</i> , 2016 , 170, 168-76	3.6	27
498	EEG correlates of visual short-term memory as neuro-cognitive endophenotypes of ADHD. <i>Neuropsychologia</i> , 2016 , 85, 91-9	3.2	22
497	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie 2016 , 1-18		
496	Psychiatrie, Psychosomatik, Psychotherapie [Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes 2016 , 1-35		
495	Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods. <i>International Journal of Methods in Psychiatric Research</i> , 2016 , 25, 3-11	4.3	3
494	The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016 , 266, 725-736	5.1	50

493	Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelin's Former Hospital. <i>Schizophrenia Bulletin</i> , 2016 , 42 Suppl 1, S81-9	1.3	3
492	A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up. <i>Schizophrenia Bulletin</i> , 2016 , 42 Suppl 1, S71-80	1.3	14
491	The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?. <i>Psychiatria Danubina</i> , 2016 , 28, 435-440	1.8	8
490	Pharmacological treatment of negative symptoms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 567-78	5.1	35
489	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 5-18	5.1	19
488	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 18, pyv042	5.8	71
487	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. <i>Brain</i> , 2015 , 138, 2059-73	11.2	99
486	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 483-501	3.8	84
485	Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dextropropylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 483-501	3.8	24
484	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015 , 25, 2318-25	1.2	89
483	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 19-27	5.1	19
482	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015 , 19, 2-7	2.4	16
481	Obsessive-compulsive disorder--A question of conscience? An fMRI study of behavioural and neurofunctional correlates of shame and guilt. <i>Journal of Psychiatric Research</i> , 2015 , 68, 354-62	5.2	16
480	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015 , 172, 617-29	11.9	111
479	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015 , 19, 158-67	2.4	17
478	The Speed of Visual Attention and Motor-Response Decisions in Adult Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2015 , 78, 107-15	7.9	23
477	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 107-16	5.1	15
476	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 76-95	3.8	116

475	Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. <i>Journal of Affective Disorders</i> , 2015 , 173, 126-33	6.6	17
474	Prinzipien der Methodik empirischer Forschung in der Psychiatrie 2015 , 1-28		
473	Standardisierte Befunddiagnostik in der Psychiatrie 2015 , 1-25		
472	Psychiatric Assessment: Negative Symptoms 2015 , 290-294		
471	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014 , 264, 567-75	5.1	31
470	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>Schizophrenia Research</i> , 2014 , 152, 478-86	3.6	24
469	Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 859-69	5.8	126
468	Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders. <i>Schizophrenia Bulletin</i> , 2014 , 40, 1140-53	1.3	235
467	The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014 , 18, 78-85	2.4	9
466	The effects of methylphenidate on whole brain intrinsic functional connectivity. <i>Human Brain Mapping</i> , 2014 , 35, 5379-88	5.9	46
465	Are antidepressants clinically useful? Conclusion of a decade of debate. <i>World Psychiatry</i> , 2014 , 13, 201-24.4	6	
464	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 51, 190-5	5.5	8
463	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1005-14	1.2	60
462	No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 405-12	5.1	13
461	Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 85-92	5.1	15
460	Neuropsychological functioning in inpatients with major depression or schizophrenia. <i>BMC Psychiatry</i> , 2013 , 13, 203	4.2	15
459	No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. <i>Annals of General Psychiatry</i> , 2013 , 12, 26	3.4	53
458	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". <i>International Journal of Psychiatry in Clinical Practice</i> , 2013 , 17, 78-89	2.4	5

457	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 65-74	5.1	15
456	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. <i>European Neuropsychopharmacology</i> , 2013 , 23, 887-94	1.2	26
455	Interference control in adult ADHD: no evidence for interference control deficits if response speed is controlled by delta plots. <i>Acta Psychologica</i> , 2013 , 143, 71-8	1.7	9
454	Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>European Neuropsychopharmacology</i> , 2013 , 23, 663-74	1.2	17
453	Treatment-resistant Depression 2013 , 21-41		1
452	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 154-219	3.8	284
451	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 2-44	3.8	264
450	Impulsivity is related to striatal dopamine transporter availability in healthy males. <i>Psychiatry Research - Neuroimaging</i> , 2013 , 211, 251-6	2.9	26
449	Reliability and plasticity of response inhibition and interference control. <i>Brain and Cognition</i> , 2013 , 81, 82-94	2.7	133
448	Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: evidence from an emotional antisaccade task. <i>Brain and Cognition</i> , 2013 , 82, 329-36	2.7	14
447	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 334-85	3.8	346
446	The potential role of Marginal Structural Models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 386-95	3.8	3
445	Methylphenidate effects on neural activity during response inhibition in healthy humans. <i>Cerebral Cortex</i> , 2013 , 23, 1179-89	5.1	46
444	Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013 , 162B, 183-90	3.5	71
443	Repeated S-ketamine infusions in therapy resistant depression: a case series. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 996-8	2.9	49
442	Driving ability according to German guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigine. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 459-62	2.9	7
441	The diagnosis and treatment of generalized anxiety disorder. <i>Deutsches A&#x0308;rztblatt International</i> , 2013 , 110, 300-9; quiz 310	2.5	33
440	Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism. <i>PLoS ONE</i> , 2013 , 8, e59395	3.7	18

439	Antipsychotic Treatment Within a Naturalistic Trial How Are We Treating Schizophrenia Patients in the Real-World? 2013 , 137-156		
438	Correspondence (reply): In reply. <i>Deutsches A&#x0308;rzteblatt International</i> , 2013 , 110, 610-1	2.5	
437	Critical trial-related criteria in acute schizophrenia studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 151-5	5.1	5
436	Subjective emotional over-arousal to neutral social scenes in paranoid schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 59-68	5.1	27
435	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 13-22	5.1	17
434	State of the art: treatment of bipolar disorders. <i>CNS Neuroscience and Therapeutics</i> , 2012 , 18, 214-8	6.8	21
433	One-year functional outcomes of naturalistically treated patients with schizophrenia. <i>Psychiatry Research</i> , 2012 , 198, 378-85	9.9	30
432	Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. <i>Methods</i> , 2012 , 56, 519-27	4.6	10
431	Study design features affecting outcome in antidepressant trials. <i>Journal of Affective Disorders</i> , 2012 , 141, 160-7	6.6	8
430	Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. <i>BMC Medicine</i> , 2012 , 10, 67	11.4	9
429	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012 , 16, 77-84	2.4	255
428	Response trajectories in "real-world" naturalistically treated schizophrenia patients. <i>Schizophrenia Research</i> , 2012 , 139, 218-24	3.6	23
427	Associations between trait impulsivity and prepotent response inhibition. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012 , 34, 1016-32	2.1	108
426	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 318-78	3.8	364
425	Schizotypy and behavioural adjustment and the role of neuroticism. <i>PLoS ONE</i> , 2012 , 7, e30078	3.7	16
424	Treatment Response in First-episode Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012 , 10, 78-87	3.4	34
423	Multivariate patterns of brain-cognition associations relating to vulnerability and clinical outcome in the at-risk mental states for psychosis. <i>Human Brain Mapping</i> , 2012 , 33, 2104-24	5.9	22
422	Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial. <i>Psychiatric Quarterly</i> , 2012 , 83, 187-207	4.1	15

421	Functional outcomes in schizophrenia: employment status as a metric of treatment outcome. <i>Current Psychiatry Reports</i> , 2012 , 14, 229-36	9.1	21
420	Psychoedukation bei Personen mit erhöhtem Psychoseerisiko. <i>Psychotherapeut</i> , 2012 , 57, 326-334	0.5	5
419	Exploring the structure of psychopathological symptoms: a re-analysis of AMDP data by robust nonmetric multidimensional scaling. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 227-38	5.1	12
418	How close is evidence to truth in evidence-based treatment of mental disorders?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 277-89	5.1	5
417	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262 Suppl 1, 1-48	5.1	93
416	Functional neural correlates of psychometric schizotypy: an fMRI study of antisaccades. <i>Psychophysiology</i> , 2012 , 49, 345-56	4.1	45
415	Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1200-15	1.3	105
414	Infectious Agents are Associated with Psychiatric Diseases. <i>Mental Illness</i> , 2012 , 4, e10	0.9	4
413	Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. <i>Journal of Psychopharmacology</i> , 2012 , 26, 744-50	4.6	19
412	Akathisia and suicidal ideation in first-episode schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 694-8	1.7	22
411	Predictors of relapse in the year after hospital discharge among patients with schizophrenia. <i>Psychiatric Services</i> , 2012 , 63, 87-90	3.3	63
410	Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. <i>Psychopathology</i> , 2012 , 45, 276-85	3.4	40
409	Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1234-46	1.3	111
408	Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 30-8	3.8	21
407	Association between brain structure and psychometric schizotypy in healthy individuals. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 544-9	3.8	48
406	Antipsychotic response in the first week predicts later efficacy. <i>Neuropsychobiology</i> , 2012 , 66, 100-5	4	10
405	Pharmacotherapy of schizophrenic patients: achievements, unsolved needs, future research necessities. <i>Current Pharmaceutical Biotechnology</i> , 2012 , 13, 1476-89	2.6	3
404	No association of a set of candidate genes on haloperidol side effects. <i>PLoS ONE</i> , 2012 , 7, e44853	3.7	7

403 Psychiatrie in Europa: Stand der Dinge, Chancen und Herausforderungen **2012**, 219-227

402	A neuropsychological investigation of the genome wide associated schizophrenia risk variant NRG1 rs12807809. <i>Schizophrenia Research</i> , 2011 , 125, 304-6	3.6	20
401	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011 , 10, 138-51	14.4	489
400	Is evaluation of humorous stimuli associated with frontal cortex morphology? A pilot study using facial micro-movement analysis and MRI. <i>Cortex</i> , 2011 , 47, 569-74	3.8	9
399	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 74-7	5.5	6
398	Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?. <i>European Neuropsychopharmacology</i> , 2011 , 21, 370-8	1.2	39
397	Effectiveness of quetiapine in outpatients with schizophrenia assessed under "real-life" conditions: a German clinical-practice evaluation programme. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 120-27	1.7	1
396	Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 405-12	5.8	99
395	Antidepressants vs. placebo: not merely a quantitative difference in response. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 1435-1437	5.8	5
394	Reception of Kraepelin's ideas 1900-1960. <i>Psychiatry and Clinical Neurosciences</i> , 2011 , 65, 318-25	6.2	18
393	Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2011 , 45, 234-41	5.2	51
392	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. <i>Journal of Psychiatric Research</i> , 2011 , 45, 309-21	5.2	112
391	Alterations of the early auditory evoked gamma-band response in first-degree relatives of patients with schizophrenia: hints to a new intermediate phenotype. <i>Journal of Psychiatric Research</i> , 2011 , 45, 699-705	5.2	49
390	Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. <i>Journal of Psychiatric Research</i> , 2011 , 45, 1639-47	5.2	20
389	Clinical predictors of response and remission in inpatients with depressive syndromes. <i>Journal of Affective Disorders</i> , 2011 , 133, 137-49	6.6	60
388	Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261, 3-10	5.1	13
387	Attention to emotion: auditory-evoked potentials in an emotional choice reaction task and personality traits as assessed by the NEO FFI. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261, 111-20	5.1	10
386	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261 Suppl 3, 207-45	5.1	29

385	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. <i>Psychopharmacology</i> , 2011 , 214, 719-28	4.7	2
384	Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. <i>Psychopharmacology</i> , 2011 , 216, 17-27	4.7	34
383	Is the PANSS used correctly? a systematic review. <i>BMC Psychiatry</i> , 2011 , 11, 113	4.2	49
382	The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. <i>Human Brain Mapping</i> , 2011 , 32, 1349-62	5.9	87
381	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 2-32	3.8	63
380	Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early--and additional memory dysfunction in the late--prodromal state. <i>Schizophrenia Bulletin</i> , 2011 , 37, 861-73	1.3	105
379	Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. <i>American Journal of Psychiatry</i> , 2011 , 168, 408-17	11.9	84
378	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011 , 10, 52-77	14.4	1288
377	NCAM1, TACR1 and NOS genes and temperament: a study on suicide attempters and controls. <i>Neuropsychobiology</i> , 2011 , 64, 32-7	4	10
376	Novel schizophrenia risk gene TCF4 influences verbal learning and memory functioning in schizophrenia patients. <i>Neuropsychobiology</i> , 2011 , 63, 131-6	4	34
375	The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. <i>Journal of Neuroscience</i> , 2011 , 31, 6684-91	6.6	70
374	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , 2011 , 9, 500-525	1.1	1
373	Disentangling the adult attention-deficit hyperactivity disorder endophenotype: parametric measurement of attention. <i>Journal of Abnormal Psychology</i> , 2011 , 120, 890-901	7	24
372	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 160-87	3.8	73
371	Effectiveness studies: advantages and disadvantages. <i>Dialogues in Clinical Neuroscience</i> , 2011 , 13, 199-207	3.7	34
370	Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 205-18	4.6	60
369	Biological Perspectives on Psychiatry for the Person. <i>International Journal of Person Centered Medicine</i> , 2011 , 1,		9
368	Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients 2011 , 93-107		

367 Suicidality and Outcome in Schizophrenia Patients **2011**, 365-382

366	Should the PANSS be rescaled?. <i>Schizophrenia Bulletin</i> , 2010 , 36, 455-60	1.3	69
365	Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 729-38	3.8	25
364	A large replication study and meta-analysis in European samples provides further support for association of AH11 markers with schizophrenia. <i>Human Molecular Genetics</i> , 2010 , 19, 1379-86	5.6	42
363	Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. <i>Archives of General Psychiatry</i> , 2010 , 67, 692-700		120
362	Review: antidepressants associated with increased risk of suicidality in adults aged less than 25 years. <i>Evidence-Based Mental Health</i> , 2010 , 13, 52	11.1	2
361	The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 447-456	3.8	13
360	Orbitofrontal volume reductions during emotion recognition in patients with major depression. <i>Journal of Psychiatry and Neuroscience</i> , 2010 , 35, 311-20	4.5	80
359	Safety evaluation of zotepine for the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 659-66	4.1	2
358	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 81-109	3.8	256
357	Childhood stress, serotonin transporter gene and brain structures in major depression. <i>Neuropsychopharmacology</i> , 2010 , 35, 1383-90	8.7	157
356	Reduced early auditory evoked gamma-band response in patients with schizophrenia. <i>Biological Psychiatry</i> , 2010 , 67, 224-31	7.9	93
355	Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. <i>Biological Psychiatry</i> , 2010 , 67, 161-7	7.9	142
354	Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. <i>Schizophrenia Research</i> , 2010 , 116, 9-15	3.6	62
353	Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis. <i>Schizophrenia Research</i> , 2010 , 123, 160-74	3.6	41
352	Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. <i>Schizophrenia Research</i> , 2010 , 123, 175-87	3.6	44
351	¿Predice la mejoría precoz inducida por los antidepresivos la respuesta/remisión? Análisis de los datos de un estudio naturalista en una muestra a gran escala de pacientes hospitalizados con depresión mayor. <i>Psiquiatría Biológica</i> , 2010 , 17, 45-53	0.2	
350	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. <i>Psychiatry Research</i> , 2010 , 179, 222-5	9.9	8

349	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. <i>European Neuropsychopharmacology</i> , 2010 , 20, 346-55	1.2	61
348	Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. <i>Schizophrenia Research</i> , 2010 , 121, 118-24	3.6	193
347	White matter microstructure underlying default mode network connectivity in the human brain. <i>NeuroImage</i> , 2010 , 49, 2021-32	7.9	155
346	Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 683-97	4.1	26
345	Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 36-44	3.8	21
344	Agomelatine: The evidence for its place in the treatment of depression. <i>Core Evidence</i> , 2010 , 4, 171-9	4.9	21
343	Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 726-31	1.7	23
342	Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 277-87	2.2	100
341	An early improvement threshold to predict response and remission in first-episode schizophrenia. <i>British Journal of Psychiatry</i> , 2010 , 196, 460-6	5.4	39
340	Altered brain activation during a verbal working memory task in subjects with amnesic mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 103-18	4.3	76
339	Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 127-37	5.1	43
338	Meta-analyses: a method to maximise the evidence from clinical studies?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 17-23	5.1	16
337	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 25-39	5.1	31
336	Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 3-16	5.1	25
335	The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 367-84	5.1	46
334	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2010 , 160, 547-56	2.9	46
333	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. <i>Journal of Psychiatric Research</i> , 2010 , 44, 487-92	5.2	21
332	Response and remission criteria in major depression--a validation of current practice. <i>Journal of Psychiatric Research</i> , 2010 , 44, 1063-8	5.2	174

331	Anterior cingulum volumetry, auditory P300 in schizophrenia with negative symptoms. <i>Psychiatry Research - Neuroimaging</i> , 2010 , 183, 133-9	2.9	13
330	The need for efficient long-term neuroleptic treatment in schizophrenic patients and the place of long acting injectable antipsychotics 2010 , 9,		78
329	Is the Overlap of Neurobiological and Psychopathological Parameters Large Enough to Give up the Dichotomic Classification?. <i>Psychiatric Annals</i> , 2010 , 40, 163-167	0.5	3
328	Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1425-33	4.6	15
327	Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1293-307	4.6	28
326	Der besondere Stellenwert von Antipsychotika der zweiten Generation in der Therapie schizophrener und affektiver Psychosen 2010 , 187-196		
325	Neuronal correlates of emotional processing in patients with major depression. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 202-8	3.8	68
324	Do "real world" studies on antipsychotics tell us the real truth?. <i>World Psychiatry</i> , 2009 , 8, 32	14.4	
323	Tyrosine hydroxylase and DOPA decarboxylase gene variants in personality traits. <i>Neuropsychobiology</i> , 2009 , 59, 23-7	4	6
322	The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 181-9	5.8	35
321	Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. <i>British Journal of Psychiatry</i> , 2009 , 195, 218-26	5.4	71
320	Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. <i>Archives of General Psychiatry</i> , 2009 , 66, 1045-54		42
319	A genome-wide investigation of SNPs and CNVs in schizophrenia. <i>PLoS Genetics</i> , 2009 , 5, e1000373	6	357
318	Prediction of symptom remission in schizophrenia during inpatient treatment. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 426-34	3.8	15
317	Disruption of the neurexin 1 gene is associated with schizophrenia. <i>Human Molecular Genetics</i> , 2009 , 18, 988-96	5.6	376
316	Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. <i>Archives of General Psychiatry</i> , 2009 , 66, 700-12		321
315	Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. <i>Psychiatry Research - Neuroimaging</i> , 2009 , 173, 183-9	2.9	18
314	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. <i>Journal of Psychiatric Research</i> , 2009 , 43, 519-25	5.2	36

313	Inefficient neural activity in patients with schizophrenia and nonpsychotic relatives of schizophrenic patients: evidence from a working memory task. <i>Journal of Psychiatric Research</i> , 2009 , 43, 1185-94	5.2	36
312	Personality and attempted suicide. Analysis of anger, aggression and impulsivity. <i>Journal of Psychiatric Research</i> , 2009 , 43, 1262-71	5.2	137
311	Attitude towards adherence in patients with schizophrenia at discharge. <i>Journal of Psychiatric Research</i> , 2009 , 43, 1294-301	5.2	22
310	Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. <i>Journal of Affective Disorders</i> , 2009 , 115, 439-49	6.6	125
309	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 434-8	3.5	7
308	Regional networks underlying interhemispheric connectivity: an EEG and DTI study in healthy ageing and amnesic mild cognitive impairment. <i>Human Brain Mapping</i> , 2009 , 30, 2098-119	5.9	72
307	The free choice whether or not to respond after stimulus presentation. <i>Human Brain Mapping</i> , 2009 , 30, 2971-85	5.9	26
306	The problem of being a paradigm: the emergence of neural stem cells as example for Kuhnian revolution in biology or misconception of the scientific community?. <i>Poiesis & Praxis</i> , 2009 , 6, 3-11		1
305	Creating a map of psychiatric patients based on psychopathological symptom profiles. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259, 164-71	5.1	13
304	Internal capsule size associated with outcome in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259, 278-83	5.1	31
303	Is evidence sufficient for evidence-based medicine?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259 Suppl 2, S167-72	5.1	9
302	Common variants conferring risk of schizophrenia. <i>Nature</i> , 2009 , 460, 744-7	50.4	1350
301	Antidepressants and suicidality in younger adults--is bipolar illness the missing link?. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 166; author reply 167	6.5	8
300	Development of DSM-V and ICD-11: tendencies and potential of new classifications in psychiatry at the current state of knowledge. <i>Psychiatry and Clinical Neurosciences</i> , 2009 , 63, 595-612	6.2	31
299	Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 111-8	2.2	76
298	Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2009 , 113, 210-7	3.6	85
297	Cardiovascular disease and diabetes in people with severe mental illness. <i>Revista De Psiquiatria Y Salud Mental</i> , 2009 , 2, 49-59	2.7	15
296	Cardiovascular disease and diabetes in people with severe mental illness. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2009 , 2, 49-59	0.2	2

295	Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 180-95	3.8	16
294	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 85-116	3.8	251
293	Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 6-26	3.8	66
292	Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 241-4	3.8	68
291	Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 147-56	1.7	30
290	Influence of 5-HT ₃ receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 843-51	1.9	26
289	White matter microstructure in relation to education in aging and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 17, 571-83	4.3	69
288	Lithium Trial in Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 922-931	4.6	208
287	Side effect burden of antipsychotic medication. <i>Medical Psychiatry</i> , 2009 , 231-259		1
286	Large recurrent microdeletions associated with schizophrenia. <i>Nature</i> , 2008 , 455, 232-6	50.4	1427
285	Identification of loci associated with schizophrenia by genome-wide association and follow-up. <i>Nature Genetics</i> , 2008 , 40, 1053-5	36.3	877
284	Cognitive functioning in euthymic bipolar I and bipolar II patients. <i>Bipolar Disorders</i> , 2008 , 10, 877-87	3.8	82
283	Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. <i>Journal of Affective Disorders</i> , 2008 , 108, 271-8	6.6	26
282	Temperament and character of suicide attempters. <i>Journal of Psychiatric Research</i> , 2008 , 42, 938-45	5.2	56
281	SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2008 , 42, 963-70	5.2	33
280	Anterior cingulate cortex does not differ between patients with major depression and healthy controls, but relatively large anterior cingulate cortex predicts a good clinical course. <i>Psychiatry Research - Neuroimaging</i> , 2008 , 163, 76-83	2.9	43
279	Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: an fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2008 , 163, 248-59	2.9	38
278	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 248-312	3.8	496

277	Evaluation of the German WPA "program against stigma and discrimination because of schizophrenia--Open the Doors": results from representative telephone surveys before and after three years of antistigma interventions. <i>Schizophrenia Research</i> , 2008 , 98, 184-93	3.6	51
276	Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. <i>Psychiatry Research</i> , 2008 , 158, 297-305	9.9	21
275	Estrogen receptor gene 1 variants are not associated with suicidal behavior. <i>Psychiatry Research</i> , 2008 , 160, 1-7	9.9	13
274	Influence of trait anxiety on inhibitory control in alcohol-dependent patients: simultaneous acquisition of ERPs and BOLD responses. <i>Journal of Psychiatric Research</i> , 2008 , 42, 734-45	5.2	49
273	Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. <i>NeuroImage</i> , 2008 , 39, 1600-12	7.9	140
272	Single-trial coupling of EEG and fMRI reveals the involvement of early anterior cingulate cortex activation in effortful decision making. <i>NeuroImage</i> , 2008 , 42, 158-68	7.9	116
271	A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2008 , 18, 122-7	1.2	47
270	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 6-23	3.8	50
269	Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 102-14	3.8	77
268	Duloxetine in the treatment of major psychiatric and neuropathic disorders. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 527-36	4.3	88
267	Depression-related variation in brain morphology over 3 years: effects of stress?. <i>Archives of General Psychiatry</i> , 2008 , 65, 1156-65		277
266	Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 217-28	5.8	56
265	The assessment of cognitive impairment would be a relevant addition to the criteria for diagnosing schizophrenia. <i>World Psychiatry</i> , 2008 , 7, 35-6	14.4	3
264	Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 477-83	5.8	18
263	Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 985-97	5.8	50
262	Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 95-105	2.2	17
261	[123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 40-7	5.1	11
260	SNAP-25 genotype influences NAA/Cho in left hippocampus. <i>Journal of Neural Transmission</i> , 2008 , 115, 1513-8	4.3	10

259	White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 278-84	5.1	13
258	Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trial of treatment with atypical antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 335-44	5.1	30
257	Do effectiveness ("real world") studies on antipsychotics tell us the real truth?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 257-70	5.1	26
256	Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 2, 48-73 ¹	5.1	74
255	Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 3, 3-23	5.1	64
254	The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 5, 7-17	5.1	13
253	Neuropsychological impairments predict the clinical course in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 5, 28-34	5.1	43
252	NOS-I and -III gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 42-8	3.5	44
251	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147, 308-15	3.5	13
250	Reduced hippocampal volumes associated with the long variant of the tri- and diallelic serotonin transporter polymorphism in major depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 1003-7	3.5	61
249	Angststörungen 2008 , 911-925		
248	Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. <i>Journal of Psychiatry and Neuroscience</i> , 2008 , 33, 423-30 ^{4.5}	4.5	195
247	Electroconvulsive therapy and its different indications. <i>Dialogues in Clinical Neuroscience</i> , 2008 , 10, 105-17 ⁷	5.7	80
246	Effects of different antidepressant treatments on the core of depression. <i>Dialogues in Clinical Neuroscience</i> , 2008 , 10, 309-20	5.7	3
245	Drug Treatment of Depressive Symptoms in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008 , 1, 328-340	1.6	10
244	The impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 899-906	4.6	36
243	The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1880-6	4.6	36
242	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. <i>World Journal of Biological Psychiatry</i> , 2007 , 8, 67-104 ^{3.8}	3.8	249

241	Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. <i>Schizophrenia Research</i> , 2007 , 97, 254-63	3.6	96
240	In-vivo topography of structural alterations of the anterior cingulate in patients with schizophrenia: new findings and comparison with the literature. <i>Schizophrenia Research</i> , 2007 , 96, 34-45	3.6	21
239	Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. <i>Drugs</i> , 2007 , 67, 1541-66	12.1	41
238	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. <i>World Journal of Biological Psychiatry</i> , 2007 , 8, 212-44	3.8	104
237	HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 291-9	3.5	66
236	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 757-61	3.5	16
235	Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. <i>Depression and Anxiety</i> , 2007 , 24, 185-95	8.4	115
234	Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. <i>Microbial Biotechnology</i> , 2007 , 1, 71-8	3.3	48
233	Prediction of treatment response in major depression: integration of concepts. <i>Journal of Affective Disorders</i> , 2007 , 98, 215-25	6.6	128
232	Hippocampal volume reduction and history of aggressive behaviour in patients with borderline personality disorder. <i>Psychiatry Research - Neuroimaging</i> , 2007 , 154, 157-70	2.9	74
231	Acute prefrontal rTMS increases striatal dopamine to a similar degree as D-amphetamine. <i>Psychiatry Research - Neuroimaging</i> , 2007 , 156, 251-5	2.9	79
230	Auditory cortex and anterior cingulate cortex sources of the early evoked gamma-band response: relationship to task difficulty and mental effort. <i>Neuropsychologia</i> , 2007 , 45, 2294-306	3.2	71
229	Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. <i>Journal of Psychiatric Research</i> , 2007 , 41, 168-73	5.2	142
228	Decreased T cellular immune response in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2007 , 41, 3-7	5.2	62
227	Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 47-53	5.1	52
226	Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 360-70	5.1	41
225	Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 402-12	5.1	36
224	Influence of anxiety on electrophysiological correlates of response inhibition capacities in alcoholism. <i>Clinical EEG and Neuroscience</i> , 2007 , 38, 89-95	2.3	12

223	Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study. <i>Cerebral Cortex</i> , 2007 , 17, 2276-82	5.1	67
222	Molecular genetic findings in suicidal behavior: what is beyond the serotonergic system?. <i>Archives of Suicide Research</i> , 2007 , 11, 17-40	2.3	57
221	Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. <i>British Journal of Psychiatry</i> , 2007 , 51, s88-95	5.4	100
220	Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. <i>Archives of General Psychiatry</i> , 2007 , 64, 410-6		316
219	Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. <i>Clinical EEG and Neuroscience</i> , 2007 , 38, 78-81	2.3	75
218	Evidence of agomelatine's antidepressant efficacy: the key points. <i>International Clinical Psychopharmacology</i> , 2007 , 22 Suppl 2, S15-9	2.2	21
217	A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 212-20	2.2	50
216	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 323-9	2.2	103
215	Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. <i>Brain</i> , 2007 , 130, 1745-58	11.2	41
214	5-HT2A SNPs and the Temperament and Character Inventory. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007 , 31, 1275-81	5.5	31
213	ABCG1 gene variants in suicidal behavior and aggression-related traits. <i>European Neuropsychopharmacology</i> , 2007 , 17, 410-6	1.2	22
212	Clinical evaluation of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2007 , 22, 380-6	6	66
211	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. <i>NeuroImage</i> , 2007 , 34, 985-95	9.9	144
210	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. <i>NeuroImage</i> , 2007 , 38, 13-24	7.9	160
209	Schizophrene und schizophreniforme Störungen 2007 , 1507-1518		
208	[I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. <i>Journal of Psychiatry and Neuroscience</i> , 2007 , 32, 234-40	4.5	39
207	Quetiapine in the treatment of schizophrenia and related disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 219-35	3.1	45
206	Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1763-74	4.6	67

205	Evaluaci3n cl3nica de los s3ntomas negativos de la esquizofrenia. <i>European Psychiatry (Ed Espa3ola)</i> , 2007 , 14, 375-382		
204	Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. <i>Psychopharmacology</i> , 2006 , 187, 86-94	4.7	51
203	Distinct seasonality of depressive episodes differentiates unipolar depressive patients with and without depressive mixed states. <i>Journal of Affective Disorders</i> , 2006 , 90, 1-5	6.6	14
202	Anger- and aggression-related traits are associated with polymorphisms in the 5-HT-2A gene. <i>Journal of Affective Disorders</i> , 2006 , 96, 75-81	6.6	87
201	Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study. <i>Journal of Psychiatric Research</i> , 2006 , 40, 307-14	5.2	129
200	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 5-40	3.8	118
199	A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. <i>Neuropsychopharmacology</i> , 2006 , 31, 1335-44	8.7	49
198	Recent progress in pharmacological and non-pharmacological treatment options of major depression. <i>Current Pharmaceutical Design</i> , 2006 , 12, 503-15	3.3	41
197	Duloxetine: a new selective and dual-acting antidepressant. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 421-7	4	18
196	GABAA receptors as targets for novel anxiolytic drugs. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 231-7	3.8	23
195	Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 198-222	3.8	37
194	The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 82-90	3.8	32
193	The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 162-70	3.8	27
192	A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. <i>Biological Psychiatry</i> , 2006 , 59, 721-9	7.9	199
191	Amygdala volume and depressive symptoms in patients with borderline personality disorder. <i>Biological Psychiatry</i> , 2006 , 60, 302-10	7.9	89
190	Factor structure and external validity of the PANSS revisited. <i>Schizophrenia Research</i> , 2006 , 82, 213-23	3.6	112
189	Long-acting risperidone: focus on safety. <i>Clinical Therapeutics</i> , 2006 , 28, 633-51	3.5	20
188	Treatment of depression with atypical features: a meta-analytic approach. <i>Psychiatry Research</i> , 2006 , 141, 89-101	9.9	97

187	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. <i>Neurobiology of Aging</i> , 2006 , 27, 10-5	5.6	60
186	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo. <i>Revista De Psiquiatria Clinica</i> , 2006 , 33, 7-64	0.8	3
185	Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 1-16	5.1	46
184	Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 329-43	5.1	46
183	Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 476-96	5.1	45
182	Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. <i>Journal of Neurology</i> , 2006 , 253, 794-800	5.5	86
181	Reduced hippocampal volume correlates with executive dysfunctioning in major depression. <i>Journal of Psychiatry and Neuroscience</i> , 2006 , 31, 316-23	4.5	171
180	The German Research Network on Schizophrenia—impact on the management of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2006 , 8, 115-21	5.7	13
179	Antidepressants and driving ability: results from a clinical study. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1776-81	4.6	59
178	Das Publizieren in der Psychiatrie 2006 , 199-221		1
177	Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. <i>Archives of Neurology</i> , 2005 , 62, 770-3		137
176	Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. <i>Brain</i> , 2005 , 128, 2626-44	11.2	182
175	ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. <i>NeuroImmunoModulation</i> , 2005 , 12, 54-9	2.5	24
174	Sound level dependence of the primary auditory cortex: Simultaneous measurement with 61-channel EEG and fMRI. <i>NeuroImage</i> , 2005 , 28, 49-58	7.9	139
173	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2005 , 6, 132-91	3.8	216
172	Fifteen-year follow-up of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorders: the prognostic significance of psychotic features. <i>Comprehensive Psychiatry</i> , 2005 , 46, 322-7	7.3	12
171	Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. <i>Biological Psychiatry</i> , 2005 , 57, 813-6	7.9	58
170	Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. <i>World Journal of Biological Psychiatry</i> , 2005 , 6, 247-63	3.8	43

169	Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. <i>International Clinical Psychopharmacology</i> , 2005 , 20, 121-30	2.2	92
168	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. <i>Journal of Psychiatric Research</i> , 2005 , 39, 101-8	5.2	39
167	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 269-78	5.1	50
166	The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 334-40	5.1	3
165	Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 83-93	5.1	48
164	Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 190-201	5.1	59
163	Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 432-7	5.1	41
162	Driving ability in schizophrenic patients: effects of neuroleptics. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005 , 9, 168-74	2.4	5
161	Risperidone: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 803-18	4	43
160	Problems associated with the classification and diagnosis of psychiatric disorders. <i>World Journal of Biological Psychiatry</i> , 2005 , 6, 45-56	3.8	19
159	Saccadic eye velocity after selective GABAergic treatment with tiagabine in healthy volunteers. <i>Neuropsychobiology</i> , 2005 , 52, 147-50	4	4
158	Schizophrene und schizophreniforme Störungen 2005 , 1342-1351		
157	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. <i>Archives of General Psychiatry</i> , 2004 , 61, 95-102		336
156	Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?. <i>Pharmacopsychiatry</i> , 2004 , 37, 110-8	2	11
155	Optimierung der pharmakologischen Langzeitbehandlung ersterkrankter schizophrener Patienten. <i>Psychoneuro: Psychiatrie - Neurologie - Psychotherapie</i> , 2004 , 30, 615-619		1
154	Classification of functional psychoses and its implication for prognosis: comparison between ICD-10 and DSM-IV. <i>Psychopathology</i> , 2004 , 37, 110-7	3.4	21
153	Novel antipsychotics in the long-term treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2004 , 5, 9-19	3.8	21
152	Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. <i>Brain</i> , 2004 , 127, 811-24	11.2	115

151	Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. <i>Neuropsychopharmacology</i> , 2004 , 29, 1910-7	8.7	49
150	Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. <i>Journal of Affective Disorders</i> , 2004 , 78, 149-52	6.6	75
149	Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. <i>Journal of Affective Disorders</i> , 2004 , 83, 237-42	6.6	21
148	Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. <i>General Hospital Psychiatry</i> , 2004 , 26, 190-8	5.6	103
147	Screening for depression in primary care: will one or two items suffice?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 215-23	5.1	53
146	COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 14-22	5.1	107
145	Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 99-107	5.1	22
144	Non-neuroleptic approaches to treating negative symptoms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 108-16	5.1	31
143	Early detection and secondary prevention of psychosis: facts and visions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 117-28	5.1	146
142	Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 129-40	5.1	42
141	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. <i>World Journal of Biological Psychiatry</i> , 2004 , 5, 120-35	3.8	104
140	Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. <i>Schizophrenia Research</i> , 2004 , 67, 175-83	3.6	52
139	Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. <i>Biological Psychiatry</i> , 2004 , 56, 581-6	7.9	173
138	Cincinnati criteria for mixed mania and suicidality in patients with acute mania. <i>Comprehensive Psychiatry</i> , 2004 , 45, 62-9	7.3	20
137	Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. <i>NeuroImage</i> , 2004 , 22, 83-94	7.9	492
136	The impact of antipsychotics on psychomotor performance with regards to car driving skills. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 155-60	1.7	47
135	Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. <i>Archives of General Psychiatry</i> , 2004 , 61, 177-83		149
134	Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 492-9	4.6	162

133	Schizoaffektive Psychosen und sonstige wahnhaftige Störungen nicht organischer Genese 2004 , 160-188		
132	Schizophrene Psychosen 2004 , 109-160		
131	Extrapyramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie 2004 , 19-60		
130	Identifying depression in primary care: a comparison of different methods in a prospective cohort study. <i>BMJ, The</i> , 2003 , 326, 200-1	5.9	195
129	Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. <i>American Journal of Psychiatry</i> , 2003 , 160, 376-9	11.9	70
128	Neurobiologische Befunde und klinische Ergebnisse. <i>Psycho</i> , 2003 , 29, 44-50		
127	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. <i>World Journal of Biological Psychiatry</i> , 2003 , 4, 5-13	3.8	124
126	Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. <i>American Journal of Psychiatry</i> , 2003 , 160, 1870-8	11.9	83
125	Improving the chance of recovery from the short- and long-term consequences of depression. <i>International Clinical Psychopharmacology</i> , 2003 , 18, 219-25	2.2	12
124	The impact of the duration of untreated psychosis on short- and long-term outcome in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2003 , 16, S39-S43	4.9	16
123	Prefrontal cortex stimulation as antidepressant treatment: mode of action and clinical effectiveness of rTMS. <i>Supplements To Clinical Neurophysiology</i> , 2003 , 56, 406-32		7
122	On the descriptive validity of ICD-10 schizophrenia: empirical analyses in the spectrum of non-affective functional psychoses. <i>Psychopathology</i> , 2003 , 36, 152-9	3.4	23
121	Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. <i>Psychopharmacology</i> , 2003 , 166, 271-5	4.7	46
120	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 22-8	5.1	48
119	Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 44-8	5.1	23
118	German research network on schizophrenia-bridging the gap between research and care. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 321-9	5.1	54
117	Effects of antidepressant pharmacotherapy after repetitive transcranial magnetic stimulation in major depression: an open follow-up study. <i>Journal of Psychiatric Research</i> , 2003 , 37, 145-53	5.2	20
116	Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. <i>Depression and Anxiety</i> , 2003 , 18, 140-3	8.4	33

115	Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior 2003 , 116B, 69-71		34
114	Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression. <i>Acta Neuropsychiatrica</i> , 2003 , 15, 217-26	3.9	8
113	Repetitive transcranial magnetic stimulation : does it have potential in the treatment of depression?. <i>CNS Drugs</i> , 2003 , 17, 383-403	6.7	34
112	Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. <i>Biological Psychiatry</i> , 2003 , 53, 338-44	7.9	209
111	Substance P serum levels are increased in major depression: preliminary results. <i>Biological Psychiatry</i> , 2003 , 53, 538-42	7.9	98
110	Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. <i>Biological Psychiatry</i> , 2003 , 54, 465-73	7.9	121
109	A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. <i>Biological Psychiatry</i> , 2003 , 54, 34-9	7.9	150
108	The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. <i>Schizophrenia Research</i> , 2003 , 62, 37-44	3.6	112
107	Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. <i>Schizophrenia Research</i> , 2003 , 64, 115-24	3.6	76
106	Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003 , 27, 1101-11	5.5	67
105	Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. <i>Biological Psychiatry</i> , 2003 , 54, 1406-13	7.9	101
104	Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. <i>Psychiatry Research</i> , 2003 , 119, 63-79	9.9	78
103	Management of the negative symptoms of schizophrenia: new treatment options. <i>CNS Drugs</i> , 2003 , 17, 793-823	6.7	95
102	Response to letter to the editor from Andrade et al. (2003) ECT in the management of major depression: Implications of recent research, <i>World J Biol Psychiatry</i> 4: 139-140. <i>World Journal of Biological Psychiatry</i> , 2003 , 4, 140-141	3.8	
101	Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. <i>Neuropsychobiology</i> , 2003 , 47, 212-8	4	24
100	Negative symptoms in depressed and schizophrenic patients: how do they differ?. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 954-8	4.6	32
99	Psychiatrische Erkrankungen 2003 , 1265-1384		
98	Bipolar disorder and schizophrenia: distinct illnesses or a continuum?. <i>Journal of Clinical Psychiatry</i> , 2003 , 64 Suppl 6, 23-7; discussion 28	4.6	27

97	Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. <i>Journal of Psychiatric Research</i> , 2002 , 36, 131-5	5.2	21
96	Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. <i>Neuropsychopharmacology</i> , 2002 , 27, 638-45	8.7	52
95	Investigation of a possible diencephalic pathology in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2002 , 115, 127-35	2.9	21
94	Handedness and corpus callosum morphology. <i>Psychiatry Research - Neuroimaging</i> , 2002 , 116, 33-42	2.9	18
93	Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. <i>Annals of Neurology</i> , 2002 , 52, 253-6	9.4	130
92	The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002 , 252, 226-31	5.1	33
91	Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. <i>Psychophysiology</i> , 2002 , 39, 175-181	4.1	93
90	Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. <i>Archives of Neurology</i> , 2002 , 59, 1267-72		225
89	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 69-86	3.8	101
88	Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. <i>American Journal of Psychiatry</i> , 2002 , 159, 968-74	11.9	100
87	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 5-43	3.8	252
86	Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. <i>American Journal of Psychiatry</i> , 2002 , 159, 1029-34	11.9	304
85	Hippocampal changes in patients with a first episode of major depression. <i>American Journal of Psychiatry</i> , 2002 , 159, 1112-8	11.9	421
84	Progression of corpus callosum atrophy in Alzheimer disease. <i>Archives of Neurology</i> , 2002 , 59, 243-8		139
83	Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2002 , 194, 15-9	3.2	40
82	Enlargement of the amygdala in patients with a first episode of major depression. <i>Biological Psychiatry</i> , 2002 , 51, 708-14	7.9	247
81	The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. <i>Schizophrenia Research</i> , 2002 , 56, 87-94	3.6	63
80	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 171-99	3.8	133

79	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 115-24	3.8	139
78	P300 subcomponents in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2002 , 36, 399-406	5.2	38
77	P300 subcomponents and clinical symptoms in schizophrenia. <i>International Journal of Psychophysiology</i> , 2002 , 43, 237-46	2.9	28
76	Switch to mania after slow rTMS of the right prefrontal cortex. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 249	4.6	25
75	Selecting methodologies for the evaluation of differences in time to response between antidepressants. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 694-9	4.6	31
74	Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 826-37	4.6	133
73	Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. <i>American Journal of Psychiatry</i> , 2001 , 158, 802-4	11.9	128
72	Prefrontal cortex modulation of mood and emotionally induced facial expressions: a transcranial magnetic stimulation study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 206-12	2.7	24
71	Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 217-24	5.1	21
70	Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251 Suppl 2, 113-20	5.1	62
69	Deficit states in schizophrenia and their association with the length of illness and gender. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 272-8	5.1	15
68	Mood-stabilisers reduce the risk of developing antidepressant-induced manic states in acute treatment of bipolar I depressed patients. <i>Journal of Affective Disorders</i> , 2001 , 63, 79-83	6.6	81
67	Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression?. <i>Journal of Affective Disorders</i> , 2001 , 67, 141-6	6.6	43
66	Vigabatrin decreases cholecystinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. <i>Neuropsychopharmacology</i> , 2001 , 25, 699-703	8.7	47
65	Past, present and future of biological psychiatry. <i>World Journal of Biological Psychiatry</i> , 2001 , 2, 156-8	3.8	
64	Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. <i>American Journal of Psychiatry</i> , 2001 , 158, 1316-9	11.9	97
63	Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. <i>Schizophrenia Research</i> , 2001 , 48, 125-36	3.6	174
62	Corpus callosum and P300 in schizophrenia. <i>Schizophrenia Research</i> , 2001 , 49, 107-19	3.6	22

61	In-vivo analysis of the human planum temporale (PT): does the definition of PT borders influence the results with regard to cerebral asymmetry and correlation with handedness?. <i>Psychiatry Research - Neuroimaging</i> , 2001 , 107, 99-115	2.9	31
60	Design of clinical trials of antidepressants: should a placebo control arm be included?. <i>CNS Drugs</i> , 2001 , 15, 755-64	6.7	24
59	Methodological issues in psychiatry: psychiatry as an empirical science. <i>World Journal of Biological Psychiatry</i> , 2001 , 2, 38-47	3.8	7
58	Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 59-65	1.7	106
57	Tiagabine improves panic and agoraphobia in panic disorder patients. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 656-7	4.6	27
56	Psychomotor Performance Under Neuroleptic Treatment in Schizophrenia. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2001 , 12, 49-53	0.5	6
55	Anxiolytic effects of vigabatrin in panic disorder. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 539-40.7	4.7	16
54	Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. <i>World Journal of Biological Psychiatry</i> , 2000 , 1, 75-91	3.8	39
53	Translations of Measurements and Scales: Opportunities and Diversities. <i>International Psychogeriatrics</i> , 2000 , 12, 391-394	3.4	8
52	Corpus callosum measurement as an in vivo indicator for neocortical neuronal integrity, but not white matter pathology, in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 470-6	6.5	13
51	Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. <i>Acta Psychiatrica Scandinavica</i> , 2000 , 102, 54-7	6.5	42
50	Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. <i>Journal of Affective Disorders</i> , 2000 , 59 Suppl 1, S5-S30	6.6	623
49	Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life". <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2000 , 250, 120-32	5.1	49
48	Platelet monoamine oxidase activity in alcoholics with and without a family history of alcoholism. <i>European Addiction Research</i> , 2000 , 6, 57-63	4.6	9
47	Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2000 , 287, 187-90	3.3	151
46	State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. <i>World Journal of Biological Psychiatry</i> , 2000 , 1, 204-14	3.8	37
45	Digitized analysis of abnormal hand-motor performance in schizophrenic patients. <i>Schizophrenia Research</i> , 2000 , 45, 133-43	3.6	45
44	Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. <i>Schizophrenia Research</i> , 2000 , 44, 145-50	3.6	43

43	Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2000 , 10, 211-7	1.2	73
42	Antidepressant treatment of bipolar depression 2000 , 387-403		
41	Social functioning in depression: a review. <i>Journal of Clinical Psychiatry</i> , 2000 , 61, 268-75	4.6	363
40	Digitized analysis of handwriting and drawing movements in healthy subjects: methods, results and perspectives. <i>Journal of Neuroscience Methods</i> , 1999 , 90, 157-69	3	80
39	In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999 , 26, 862-8	8.8	21
38	Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. <i>Brain Research</i> , 1999 , 823, 104-12	3.7	73
37	Atypical neuroleptics: a new approach in the treatment of negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999 , 249 Suppl 4, 99-107	5.1	36
36	Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999 , 249 Suppl 4, 27-36	5.1	24
35	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. <i>Neuroscience Letters</i> , 1999 , 259, 145-8	3.3	50
34	Cerebrospinal fluid tau protein shows a better discrimination in young old (. <i>Neuroscience Letters</i> , 1999 , 277, 21-4	3.3	55
33	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. <i>Psychiatry Research</i> , 1999 , 88, 107-17	9.9	146
32	Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. <i>Psychiatry Research</i> , 1999 , 88, 163-71	9.9	235
31	P300 subcomponents reflect different aspects of psychopathology in schizophrenia. <i>Biological Psychiatry</i> , 1999 , 45, 116-26	7.9	55
30	Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. <i>Archives of Neurology</i> , 1999 , 56, 467-73		46
29	Effectiveness and safety of benzodiazepines. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 2S-11S	1.7	41
28	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. <i>Archives of Suicide Research</i> , 1998 , 4, 143-155	2.3	
27	Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. <i>Brain Research</i> , 1998 , 780, 356-9	3.7	47
26	A review of the reversible MAO-A inhibitor moclobemide in geriatric patients. <i>Human Psychopharmacology</i> , 1998 , 13, 43-51	2.3	3

25	The serotonin syndrome scale: first results on validity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 96-103	5.1	125
24	Risk factors for suicides of inpatients with depressive psychoses. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 141-7	5.1	35
23	Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 296-300	5.1	39
22	Markers from event-related potential subcomponents and reaction time for information processing dysfunction in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998 , 248, 307-13	5.1	20
21	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. <i>Archives of Suicide Research</i> , 1998 , 4, 143-155	2.3	3
20	Electroencephalography as a diagnostic instrument in Alzheimer's disease: reviews and perspectives. <i>International Psychogeriatrics</i> , 1997 , 9 Suppl 1, 237-46; discussion 247-52	3.4	13
19	The value of selective serotonin re-uptake inhibitors (SSRIs) in the treatment of panic disorder with and without agoraphobia. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1, 59-67	2.4	4
18	Propentofylline. <i>CNS Drugs</i> , 1997 , 8, 265	6.7	
17	Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 1997 , 228, 143-6	3.3	55
16	Brofaromine versus imipramine in in-patients with major depression--a controlled trial. <i>Journal of Affective Disorders</i> , 1997 , 44, 91-9	6.6	6
15	Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics 1997 , 174, 255-259		91
14	Dipole localization and test-retest reliability of frequency and duration mismatch negativity generator processes. <i>Brain Topography</i> , 1997 , 10, 3-8	4.3	64
13	Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial cases. <i>Schizophrenia Research</i> , 1996 , 20, 181-6	3.6	21
12	Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. <i>Drugs</i> , 1996 , 52, 625-38	12.1	47
11	Brofaromine. <i>CNS Drugs</i> , 1995 , 3, 1-8	6.7	7
10	Newer and Older Monoamine Oxidase Inhibitors. <i>CNS Drugs</i> , 1995 , 3, 145-158	6.7	46
9	Dementia Treatment: A German Perspective on Psychosocial Aspects and Therapeutic Approaches. <i>International Psychogeriatrics</i> , 1995 , 7, 459-470	3.4	1
8	Involvement of mesial-temporal structures in rapid cycling mood disorders?. <i>Human Psychopharmacology</i> , 1995 , 10, 475-480	2.3	1

7	A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1995 , 245, 45-9	5.1	106
6	Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. <i>Neuropsychobiology</i> , 1994 , 30, 160-72	4	39
5	Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. <i>European Neuropsychopharmacology</i> , 1993 , 3, 13-21	1.2	54
4	A serine to glycine substitution at position 9 in the extracellular N-terminal part of the dopamine D3 receptor protein: no role in the genetic predisposition to bipolar affective disorder. <i>Psychiatry Research</i> , 1993 , 46, 253-9	9.9	51
3	Familial cosegregation of affective disorder and Hailey-Hailey disease. <i>British Journal of Psychiatry</i> , 1993 , 163, 109-10	5.4	16
2	Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs) 1993 , 163-182		1
1	Der Verlauf schizophrener Psychosen 1986 ,		75